Small brain-penetrating molecule offers hope for treating aggressive brain tumors

 The study found that gliadin acts on specific cellular pathways to selectively kill glioblastoma cells without harming normal cells. Moreover, the compound can penetrate the blood-brain barrier, which highlights its potential as a treatment option for glioblastoma.

Background

Glioblastoma is one of the most lethal forms of brain cancer and is known for its resistance to standard therapies. Despite significant advances in cancer therapies, currently used immunotherapies and targeted therapies have had minimal success in improving survival rates in glioblastoma. This resistance is believed to stem from several challenges unique to glioblastoma, such as its complex cellular heterogeneity and immune-evasive characteristics.

Additionally, crossing the blood-brain barrier to reach tumor cells remains a significant obstacle. Researchers are exploring novel metabolic pathways as potential therapeutic targets. Unlike typical cancer drugs that inhibit cell division, some emerging therapies aim to disrupt cancer-specific vulnerabilities. The use of prodrugs, which are converted into active drugs within the body, is gaining special attention due to their ability to target malignant cells while sparing healthy tissue selectively.


About the study

In the present study, the researchers aimed to identify a compound that could selectively target glioblastoma cells. A high-throughput chemical screen of over 200,000 compounds was conducted using low-passage glioblastoma cells derived from genetically engineered mouse models. Compounds toxic to normal replicative cells were excluded. The screening identified gliocidin as a promising candidate due to its selective toxicity against glioblastoma cells.

To investigate the mechanism of action, the team then employed multiple experimental approaches. Genetic analyses were performed using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) screens to identify pathways and enzymes essential for the activity of gliocidin.

Pharmacokinetics and biodistribution studies in animal models were used to determine the ability of gliocidin to cross the blood-brain barrier and maintain effective concentrations in the brain. The researchers used glioblastoma-bearing mouse models to test the brain penetration abilities and bioavailability of gliocidin. Drug administration was optimized using intraperitoneal injection, and tissue analysis was used to confirm its presence in the brain.

Additionally, the researchers used liquid chromatography-mass spectrometry (LC-MS) to measure the levels of intermediate compounds and final metabolites in cells and tissues to understand gliocidin metabolism.

Website Link: molecularbiologist.org/

Contact Mail ID : contact@molecularbiologist.org

Nomination Link  : https://molecularbiologist.org/award-nomination/?ecategory=Awards&rcategory=Awardee

Follow On:

Twitterhttps://x.com/Camilla532645                                                                   

Blogger https://molecularconference.blogspot.com/ 

Youtube https://www.youtube.com/channel/UCehrwFGWKbQa0mKDDNJCwvA                  

Pinterest https://in.pinterest.com/molecularbiologistawards/                   

Linkedin https://www.linkedin.com/feed/?trk=onboarding-landing               

Instagram https://www.instagram.com/molecularawards

#BrainTumorTreatment #Glioblastoma #BrainCancer #Neuroscience #MedicalBreakthrough #CancerResearch #SmallMoleculeTherapy #TargetedTherapy #NeuroOncology #BrainHealth #TumorPenetrating #CancerFighting #PrecisionMedicine #InnovativeTherapy #BiomedicalScience #PharmaResearch #AggressiveCancer #CNSDrugs #BrainTumorAwareness #HopeForCancer #ClinicalResearch #TumorTreatment #CancerInnovation #BrainCancerCure #OncologyResearch #NeuroTherapy #LifeSavingScience #MedicalInnovation #TherapeuticAdvances #NewCancerHope


Comments

Popular posts from this blog

Uncovering the molecular drivers of liver cancer

Why Vitamin D Deficiency Can Raise Autoimmune Disease Risk

How to determine the molecular weight of a monoclonal antibody